Page 3 - Carlos Chaccour News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Carlos chaccour. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Carlos Chaccour Today - Breaking & Trending Today

Popular drug does not alleviate mild COVID symptoms: Study


Popular drug does not alleviate mild COVID symptoms: Study
SECTIONS
Last Updated: Mar 05, 2021, 10:22 AM IST
Share
Synopsis
Some studies have indicated that Ivermectin can prevent several different viruses from replicating in cells. And last year, researchers in Australia found that high doses of ivermectin suppressed SARS-CoV-2, the virus that causes COVID-19, in cell cultures.
AFP
Such findings had spurred use of the drug against COVID-19, especially in Latin America.
Ivermectin, a controversial anti-parasitic drug that has been touted as a potential COVID-19 treatment, does not speed recovery in people with mild cases of the disease, according to a randomized controlled trial published Thursday in the journal JAMA. ....

United States , Comunidad Autonoma De Cataluna , Carlos Chaccour , Regina Rabinovich , National Institutes Of Health , Barcelona Institute For Global Health , Pediatric Infectious Diseases , Barcelona Institute , Global Health , National Institutes , Public Health , Co Vid , Latin America , ஒன்றுபட்டது மாநிலங்களில் , காமுனிடட தன்னாட்சி டி கடலுள் , தேசிய நிறுவனங்கள் ஆஃப் ஆரோக்கியம் , பார்சிலோனா நிறுவனம் க்கு உலகளாவிய ஆரோக்கியம் , குழந்தை தொற்று நோய்கள் , பார்சிலோனா நிறுவனம் , உலகளாவிய ஆரோக்கியம் , தேசிய நிறுவனங்கள் , பொது ஆரோக்கியம் , இணை வித் , லத்தீன் அமெரிக்கா ,

A clinical trial provides encouraging results on ivermectin for reducing mild COVID-19


Credit: ISGlobal/Clínica Universidad de Navarra.
A small pilot study suggests that early administration of ivermectin can reduce viral loads and symptom duration in patients with mild COVID-19, which in turn could help reduce viral transmission. The study, which is part of the SAINT project and has been led by the University of Navarra Clinic and the Barcelona Institute for Global Health (ISGlobal), an institution supported by the la Caixa Foundation, warrants further exploration in larger clinical trials. The findings of the pilot study have been published in
EClinicalMedicine, a clinical journal published by The Lancet.
We already have two approved COVID-19 vaccines in the European Union, but immunising enough people worldwide to stop viral spread will require at least two years. Meanwhile, finding drugs that can treat or prevent infections remains a priority. Many efforts are focusing on developing treatments for COVID-19, but few are addressing how to reduce ....

United States , Comunidad Autonoma De Cataluna , Carlos Chaccour , University Of Navarra Clinic , University Of Barcelona , Global Development , Pompeu Fabra University , Pasteur Institute , Barcelona Institute For Global Health , Severo Ochoa Centre Of Excellence , Caixa Foundation , Barcelona Institute For Global Health Isglobal , University Of Navarra , European Union , Navarra Clinic , Barcelona Institute , Global Health , Blanco Di Matteo , Parc De Salut , Pompeu Fabra , Severo Ochoa Centre , Medicine Health , Clinical Trials , Infectious Emerging Diseases , Public Health , ஒன்றுபட்டது மாநிலங்களில் ,